Haemonetics Corp.

Haemonetics Corporation is a publicly traded medical technology company founded in 1971. Headquartered in Boston, Massachusetts, it trades on the New York Stock Exchange under the ticker HAE. For its 2024 fiscal year, the company reported revenue of $1.3 billion. Haemonetics employs approximately 3,000 to 3,300 people.

Haemonetics is an operating company that provides medical products and solutions for blood and plasma collection, surgical procedures, and hospital transfusion services. The company's portfolio is organized into three main segments: Plasma, Blood Center, and Hospital. Its offerings include automated blood and plasma component collection systems (such as the NexSys PCS®), donor management software, surgical blood salvage systems (autotransfusion), and viscoelastic testing systems like TEG®. Haemonetics aims to improve patient care and reduce healthcare costs by enhancing the safety, quality, and efficiency of the blood supply chain.

As a medical device manufacturer, Haemonetics is an operating company that appears to be an active litigant defending its market and technology. The provided case data shows Haemonetics as both a plaintiff and a defendant in patent disputes. With one case as plaintiff and two as defendant, the company demonstrates a willingness to enforce its own patent rights while also facing assertions from competitors.

All three tracked patent cases involve the same competitor, Terumo BCT, Inc. The litigation includes one case filed by Haemonetics in the U.S. District Court for the District of Colorado and two subsequent cases where Haemonetics is the defendant in proceedings before the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB). This pattern of litigation suggests a focused, two-way dispute between direct competitors in the blood and plasma technology sector.